Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Device export approval streamlining

This article was originally published in The Gray Sheet

Executive Summary

FDA will provide industry with correspondence in about a month outlining further streamlining of its export approval policy for devices bound for European Community member countries, agency staffers say. Changes in the type of safety data required under section 801(e) of the Food, Drug and Cosmetic Act are expected. The agency has said it is likely to use the CE mark of approval in its export approval program ("The Gray Sheet" May 23, p. 16). FDA's Office of Compliance also reports average turn-around times of 20 days for 801(e) clearances and 15 days for certificates for export for the first five months of 1994, an improvement over the 1993 averages Of 65 days and 52 days, respectively

Latest Headlines
See All
UsernamePublicRestriction

Register

MT002676

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel